Skip to Main Content

Author Details

Suzanne Carreira
The Institute of Cancer Research
1990
82
39
PMIDPaper TitleJournal TitlePublished Year
36114082B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.Eur Urol2023
37844613Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.Nature2023
37284046Germline <i>ATM</i> Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer.Eur Urol Open Sci2023
37131595DNA damage-induced interaction between a lineage addiction oncogenic transcription factor and the MRN complex shapes a tissue-specific DNA Damage Response and cancer predisposition.bioRxiv2023
36964041Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38].Eur Urol2023
37355762Critical role of antioxidant programs in enzalutamide-resistant prostate cancer.Oncogene2023
36609007A Transgender Patient with Prostate Cancer: Lessons Learnt.Eur Urol2023
35552383Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer.Clin Cancer Res2022
35349486Targeting radioresistance and replication fork stability in prostate cancer.JCI Insight2022
35491356Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer.Eur Urol Oncol2022
35717027Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.J Immunother Cancer2022
32988971Characterizing CDK12-Mutated Prostate Cancers.Clin Cancer Res2021
33822745JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.Cancer Res2021
33549985Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience.Cancer Treat Res Commun2021
34753775HER3 Is an Actionable Target in Advanced Prostate Cancer.Cancer Res2021
34045297Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.Cancer Discov2021
34103179Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.Eur Urol2021
34084213HER3 expression and MEK activation in non-small-cell lung carcinoma.Lung Cancer Manag2021
33176972Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.Eur Urol2021
31605223Genetic Analysis of Circulating Tumour Cells.Recent Results Cancer Res2020
31874108Genomics of lethal prostate cancer at diagnosis and castration resistance.J Clin Invest2020
31932493Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.Clin Cancer Res2020
31806540Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.Lancet Oncol2020
33128873Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.Lancet Oncol2020
32653323Elucidating Durable Responses to Immune Checkpoint Inhibition.Eur Urol2020
32219437Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer.J Exp Med2020
32169873Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.J Immunother Cancer2020
32568634Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.J Clin Oncol2020
32343676The landscape of RNA polymerase II-associated chromatin interactions in prostate cancer.J Clin Invest2020
32532747Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers.Cancer Discov2020
30334814Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.J Clin Invest2019
30257982RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2019
31262731Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in <i>KRAS</i>-Mutant Cancers.Mol Cancer Ther2019
31345636Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.Eur Urol2019
30954315PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers.Eur Urol2019
31036442Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.Eur Urol2019
31061129Genomic correlates of clinical outcome in advanced prostate cancer.Proc Natl Acad Sci U S A2019
30340782Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.Eur Urol2019
29429804Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.Eur Urol2018
30016392Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.Ann Oncol2018
30179225Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.J Clin Invest2018
30068710SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.Clin Cancer Res2018
30042009Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.Clin Colorectal Cancer2018
30093450Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.Clin Cancer Res2018
30065256Detection of circulating tumour cell clusters in human glioblastoma.Br J Cancer2018
30382943Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.J Clin Invest2018
29555663Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).Clin Cancer Res2018
29500065Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).Eur Urol2018
28751446Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.Clin Cancer Res2017
28381424GSK-3-mediated phosphorylation couples ER-Golgi transport and nuclear stabilization of the CREB-H transcription factor to mediate apolipoprotein secretion.Mol Biol Cell2017
  • 1 - 50 of 82

Recommended Authors

Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 9
Svitlana Tyekucheva
Dana-Farber Cancer Institute
Career Start Year 2006
Number of shared co-authors 11
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 30
Robert H Bell
University of British Columbia
Career Start Year 2004
Number of shared co-authors 7
Jianmin Wang
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 4
Andrew V Kossenkov
The Wistar Institute
Career Start Year 2003
Number of shared co-authors 3
Syed Haider
Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 10
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 0
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 27
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Leena Latonen
Foundation for the Finnish Cancer Institute
Career Start Year 1999
Number of shared co-authors 0
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 17
Jianjun Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 2
Paul T Spellman
Oregon Health & Science University Hospital.
Career Start Year 1998
Number of shared co-authors 6
Ian G Mills
Queen's University Belfast
Career Start Year 1997
Number of shared co-authors 17
Benedikt Brors
German Cancer Research Center (DKFZ)
Career Start Year 1997
Number of shared co-authors 8
Robert L Walker
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 1
Agnes Viale
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 14
Holger S??ltmann
German Cancer Research Center (DKFZ)
Career Start Year 1993
Number of shared co-authors 3
Christopher M Hovens
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 9
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 10
Javed Siddiqui
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 1988
Number of shared co-authors 55
Colin C Collins
University of British Columbia
Career Start Year 1988
Number of shared co-authors 27
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 3
Eivind Hovig
Center for Bioinformatics, University of Oslo
Career Start Year 1987
Number of shared co-authors 2
Olli Kallioniemi
Karolinska Institute
Career Start Year 1984
Number of shared co-authors 3
Andrew D Cherniack
Dana-Farber Cancer Institute
Career Start Year 1984
Number of shared co-authors 9
Edison T Liu
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 1
David M Berman
Queen's University
Career Start Year 1982
Number of shared co-authors 8
David J Adams
Wellcome Sanger Institute
Career Start Year 1980
Number of shared co-authors 6

Collaborators

Johann S de Bono
The Institute for Cancer Research
Co-authored papers 59
Wei Yuan
The Institute for Cancer Research
Co-authored papers 37
Susana Miranda
The Institute of Cancer Research
Co-authored papers 33
Nina Tunariu
The Institute of Cancer Research
Co-authored papers 27
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Co-authored papers 25
Adam Sharp
The Institute for Cancer Research
Co-authored papers 25
Alec Paschalis
The Institute for Cancer Research
Co-authored papers 15
Maryou B Lambros
The Institute of Cancer Research
Co-authored papers 13
Colin R Goding
Ludwig Institute for Cancer Research, University of Oxford
Co-authored papers 12
Gunther Boysen
Co-authored papers 12
Penny Flohr
The Institute of Cancer Research
Co-authored papers 11
Zafeiris Zafeiriou
Theageneion Anticancer Hospital
Co-authored papers 10
Matthew Clarke
Co-authored papers 9
Gerhardt Attard
The Institute of Cancer Research
Co-authored papers 8
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 8
Raquel Perez-Lopez
Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus
Co-authored papers 8
Dan R Robinson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 7
Mark A Rubin
University of Bern
Co-authored papers 7
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 6
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 6
Roberta Ferraldeschi
Astex Pharmaceuticals
Co-authored papers 6
Stephen R Plymate
University of Washington
Co-authored papers 6
Lionel Larue
Institut Curie, PSL Research University, INSERM U1021
Co-authored papers 5
Howard I Scher
Memorial Sloan Kettering Cancer Center
Co-authored papers 5
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 5
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Co-authored papers 4
Ram S Mani
UT Southwestern Medical Center
Co-authored papers 4
Francesca Demichelis
University of Trento
Co-authored papers 4
Wassim Abida
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Release 1.2